For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended an update to Novo ...

Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms ...

Tectonic Therapeutics Inc. (TECX) announced favorable Phase 1a topline data for its lead asset, TX45, a long-acting, potentially ...

Thus, semaglutide is on a trajectory to finally provide a long-awaited treatment for HFpEF patients. According to GlobalData’s Pharma Intelligence Center, there are five Phase III candidates ...

Bagsværd, Denmark Saturday, September 21, 2024, 15:00 Hrs [IST] ...

TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the ...

candidate for the treatment of heart failure with preserved ejection fraction (HFpEF). Cytokinetics shared comprehensive data from the study, which showed that CK-586 was safe and well tolerated ...

The presentation detailed the results from the Phase 1 clinical trial of CK-586, Cytokinetics' second cardiac myosin inhibitor (CMI) candidate for the treatment of heart failure with preserved ...

In addition to improving heart failure symptoms, finerenone reduced the onset of new type 2 diabetes in patients with mildly ...

Quotient Sciences, Vasa Therapeutics dose first human subjects with VS-041, a novel therapy for heart failure with preserved ejection fraction: Nottingham, UK Monday, September 16 ...